A.M. Mykh
A.M. Mykh has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- O. I. Dorosh
Danylo Halytsky Lviv National Medical University, Ukraine; NPE LRC Clinical Center of Pediatrics, SP Specialized Center, Lviv, Ukraine
11 shared publications - L.P. Seredych8 shared publications
- I.P. Tsymbalyuk-Voloshyn5 shared publications
- I.P. Melko
Львівський національний медичний університет імені Данила Галицького
4 shared publications - O.A. Petronchak
ТзОВ «Західноукраїнська гістологічна лабораторія», м. Львів
4 shared publications - A.I. Stepanyuk
Ternopil Volodymyr Hnatiuk National Pedagogical University
3 shared publications
Latest Publications
- 28 October 2025
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(150),p. 94-103
TLR7-associated primary pure red cell aplasia in a boy with multigenic modifiers
Primary pure red cell aplasia (PRCA) in infants is a rare condition characterized by isolated suppression of erythropoiesis in the bone marrow. In children, it most commonly has a viral or autoimmune origin; however, isolated cases are associated with primary genetically determined immune dysregulation. TLR7 mutations have infrequently been described as a key factor in the development of PRCA in early childhood. Expanded genetic analysis enables the detection of causative and concurrent variants, as well as mosaic structural chromosomal abnormalities that may modify the clinical phenotype and immune dysregulation. Aim - to describe a clinical case of PRCA in a boy with a hemizygous TLR7 mutation, accompanying genetic modifiers, and immune dysregulation, including disproportion of lymphocyte subpopulations and marked hypogammaglobulinemia. Clinical case. At 9 months of age, the boy first diagnosed with transfusion-dependent anemia accompanied by a severe decrease in reticulocytes, hepatosplenomegaly, and a strongly positive direct Coombs test without evidence of hemolysis. Bone marrow examination revealed a marked reduction of the erythroid lineage while overall cellularity was preserved. Lymphocyte analysis revealed normal total counts but a mild disproportion, with increased B cells and decreased T cells, while the CD4/CD8 ratio remained normal. Hypogammaglobulinemia detected without infectious manifestations, along with elevated liver enzymes. Genetic testing identified a hemizygous TLR7 mutation (p.His1038Tyr), concomitant heterozygous variants in SPTA1, TTC7A, HFE, FANCF, FANCM, as well as mosaic deletions in 9p23-p21.1 and 7p14.1-р14.1. The peripheral blood smear demonstrated ovalocytes, correlating with the SPTA1 variant. Treatment with prednisolone, intravenous immunoglobulin, deferasirox led to a positive clinical and laboratory response. Conclusions. The TLR7-mutated gene is a principal driver of PRCA, while accompanying genetic variants and mosaic deletions contribute to a polygenic, modified phenotype, influencing disease severity, erythrocyte morphology, and immune dysregulation, including disproportion of lymphocyte subpopulations and marked hypogammaglobulinemia. These findings emphasize the importance of comprehensive genetic and immunological evaluation in children with rare forms of PRCA. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.
- 28 October 2025
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(150),p. 94-103
TLR7-associated primary pure red cell aplasia in a boy with multigenic modifiers
Primary pure red cell aplasia (PRCA) in infants is a rare condition characterized by isolated suppression of erythropoiesis in the bone marrow. In children, it most commonly has a viral or autoimmune origin; however, isolated cases are associated with primary genetically determined immune dysregulation. TLR7 mutations have infrequently been described as a key factor in the development of PRCA in early childhood. Expanded genetic analysis enables the detection of causative and concurrent variants, as well as mosaic structural chromosomal abnormalities that may modify the clinical phenotype and immune dysregulation. Aim - to describe a clinical case of PRCA in a boy with a hemizygous TLR7 mutation, accompanying genetic modifiers, and immune dysregulation, including disproportion of lymphocyte subpopulations and marked hypogammaglobulinemia. Clinical case. At 9 months of age, the boy first diagnosed with transfusion-dependent anemia accompanied by a severe decrease in reticulocytes, hepatosplenomegaly, and a strongly positive direct Coombs test without evidence of hemolysis. Bone marrow examination revealed a marked reduction of the erythroid lineage while overall cellularity was preserved. Lymphocyte analysis revealed normal total counts but a mild disproportion, with increased B cells and decreased T cells, while the CD4/CD8 ratio remained normal. Hypogammaglobulinemia detected without infectious manifestations, along with elevated liver enzymes. Genetic testing identified a hemizygous TLR7 mutation (p.His1038Tyr), concomitant heterozygous variants in SPTA1, TTC7A, HFE, FANCF, FANCM, as well as mosaic deletions in 9p23-p21.1 and 7p14.1-р14.1. The peripheral blood smear demonstrated ovalocytes, correlating with the SPTA1 variant. Treatment with prednisolone, intravenous immunoglobulin, deferasirox led to a positive clinical and laboratory response. Conclusions. The TLR7-mutated gene is a principal driver of PRCA, while accompanying genetic variants and mosaic deletions contribute to a polygenic, modified phenotype, influencing disease severity, erythrocyte morphology, and immune dysregulation, including disproportion of lymphocyte subpopulations and marked hypogammaglobulinemia. These findings emphasize the importance of comprehensive genetic and immunological evaluation in children with rare forms of PRCA. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies.
- Open Access
- 28 September 2024
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 5(141),p. 104-112
Late onset of familial haemophagocytic lymphohistiocytosis 2 associated with heterozygous PRF1 mutation: challenges in diagnosis and treatment
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition caused by immune overactivation. Familial HLH (f-HLH), such as f-HLH 2, is associated with mutations in the PRF1 gene, essential for ruling out secondary HLH. Aim - to describe a clinical case of late onset f-HLH 2 associated with a heterozygous mutation in the PRF1 gene in a 13-year-old boy. Case report. A 13-year-old boy presented with fever, nausea, vomiting, abdominal pain, and jaundice. Examination revealed hepatosplenomegaly, elevated liver enzymes, hyperbilirubinemia, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, and reduced NK-cells and T-lymphocytes. Cytomegalovirus (CMV) was detected by polymerase chain reaction. Pancytopenia soon developed. Bone marrow biopsy confirmed hemophagocytosis, leading to a diagnosis of secondary HLH associated with CMV. Treatment included intravenous immunoglobulin, HLH 2004 protocol (without etoposide), and ganciclovir, with initial improvement. However, cytopenia recurred after dexamethasone was stopped. Ruxolitinib was introduced alongside cyclosporine (CsA), leading to normalisation of liver function, spleen size, lymphocyte subpopulations, and haemogram. Cytopenia returned after ruxolitinib cessation. Whole-exome sequencing revealed a heterozygous PRF1 gene mutation, confirming the diagnosis of f-HLH 2. Conclusions. Timely laboratory diagnostics, bone marrow biopsy, genetic testing, and appropriate treatment are critical in preventing complications and improving outcomes in HLH. Early intervention with specific therapies, such as immunosuppressants and genetic evaluation, is essential in managing f-HLH 2. The study was conducted in accordance with the principles of the Declaration of Helsinki. The informed consent of the child's parents was obtained for the study. The authors declare no conflict of interest.
- 28 September 2024
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 5(141),p. 104-112
Open AccessLate onset of familial haemophagocytic lymphohistiocytosis 2 associated with heterozygous PRF1 mutation: challenges in diagnosis and treatment
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening condition caused by immune overactivation. Familial HLH (f-HLH), such as f-HLH 2, is associated with mutations in the PRF1 gene, essential for ruling out secondary HLH. Aim - to describe a clinical case of late onset f-HLH 2 associated with a heterozygous mutation in the PRF1 gene in a 13-year-old boy. Case report. A 13-year-old boy presented with fever, nausea, vomiting, abdominal pain, and jaundice. Examination revealed hepatosplenomegaly, elevated liver enzymes, hyperbilirubinemia, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, and reduced NK-cells and T-lymphocytes. Cytomegalovirus (CMV) was detected by polymerase chain reaction. Pancytopenia soon developed. Bone marrow biopsy confirmed hemophagocytosis, leading to a diagnosis of secondary HLH associated with CMV. Treatment included intravenous immunoglobulin, HLH 2004 protocol (without etoposide), and ganciclovir, with initial improvement. However, cytopenia recurred after dexamethasone was stopped. Ruxolitinib was introduced alongside cyclosporine (CsA), leading to normalisation of liver function, spleen size, lymphocyte subpopulations, and haemogram. Cytopenia returned after ruxolitinib cessation. Whole-exome sequencing revealed a heterozygous PRF1 gene mutation, confirming the diagnosis of f-HLH 2. Conclusions. Timely laboratory diagnostics, bone marrow biopsy, genetic testing, and appropriate treatment are critical in preventing complications and improving outcomes in HLH. Early intervention with specific therapies, such as immunosuppressants and genetic evaluation, is essential in managing f-HLH 2. The study was conducted in accordance with the principles of the Declaration of Helsinki. The informed consent of the child's parents was obtained for the study. The authors declare no conflict of interest.
- 28 November 2023
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 7(135),p. 113-121
An (un)fortunate case as the impetus for the diagnosis of MYH9-related disease in a 16-year-old boy. Clinical case
- 28 November 2023
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 7(135),p. 113-121
An (un)fortunate case as the impetus for the diagnosis of MYH9-related disease in a 16-year-old boy. Clinical case
- Open Access
- 28 October 2023
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(134),p. 133-141
Genetic verification of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene masquerading as hemoblastosis. Clinical case
Familial autoinflammatory syndrome with or without immunodeficiency (AISIMD), caused by a heterozygous mutation in the SOCS1 gene on chromosome 16p13, is characterized by the appearance of various autoimmune signs usually in the first decades of life, although later onset has been reported. Typical features of AISIMD include autoimmune cytopenia, thrombocytopenia, hemolytic anemia and lymphadenopathy, possible alterations in cellular immunity, and hypogammaglobulinemia. Purpose - to present a combination of clinical, imaging and laboratory signs in a nine-year-old patient with autoinflammatory syndrome and mild immunodeficiency caused by a heterozygous mutation in the SOCS1 gene; to emphasise the importance of genetic tests for definitive diagnosis. Clinical case. Features of diagnosis of autoinflammatory syndrome caused by heterozygous mutation in the SOCS1 gene in a 9-year-old boy are described. The disease was manifested in the laboratory by leukopenia with neutropenia, monocytosis, thrombocytopenia, an increase in markers of inflammation - C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), impaired cellular immunity (inverse CD4/CD8 ratio, reduced number of NK cells (CD3-CD16+CD56+), decrease in CD19, increase in the per cent of double-negative T-lymphocytes (Neg. In T- Double LF (CD3+CD4-CD8-); clinical: hyperthermia, recurrent aphthous stomatitis, irritable bowel syndrome, progressive generalized lymphoproliferative syndrome. Differential diagnosis with hemoblastosis was carried out, which was denied. Subsequently the presence of an ulcer in the ileum and mucinous metaplasia in the covering epithelium gave grounds to diagnose an inflammatory bowel disease: Crohn's disease with damage to the terminal part of the small intestine. Verification of the final diagnosis of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene took place using genome sequencing. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 28 October 2023
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 6(134),p. 133-141
Open AccessGenetic verification of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene masquerading as hemoblastosis. Clinical case
Familial autoinflammatory syndrome with or without immunodeficiency (AISIMD), caused by a heterozygous mutation in the SOCS1 gene on chromosome 16p13, is characterized by the appearance of various autoimmune signs usually in the first decades of life, although later onset has been reported. Typical features of AISIMD include autoimmune cytopenia, thrombocytopenia, hemolytic anemia and lymphadenopathy, possible alterations in cellular immunity, and hypogammaglobulinemia. Purpose - to present a combination of clinical, imaging and laboratory signs in a nine-year-old patient with autoinflammatory syndrome and mild immunodeficiency caused by a heterozygous mutation in the SOCS1 gene; to emphasise the importance of genetic tests for definitive diagnosis. Clinical case. Features of diagnosis of autoinflammatory syndrome caused by heterozygous mutation in the SOCS1 gene in a 9-year-old boy are described. The disease was manifested in the laboratory by leukopenia with neutropenia, monocytosis, thrombocytopenia, an increase in markers of inflammation - C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), impaired cellular immunity (inverse CD4/CD8 ratio, reduced number of NK cells (CD3-CD16+CD56+), decrease in CD19, increase in the per cent of double-negative T-lymphocytes (Neg. In T- Double LF (CD3+CD4-CD8-); clinical: hyperthermia, recurrent aphthous stomatitis, irritable bowel syndrome, progressive generalized lymphoproliferative syndrome. Differential diagnosis with hemoblastosis was carried out, which was denied. Subsequently the presence of an ulcer in the ileum and mucinous metaplasia in the covering epithelium gave grounds to diagnose an inflammatory bowel disease: Crohn's disease with damage to the terminal part of the small intestine. Verification of the final diagnosis of an autoinflammatory syndrome caused by a heterozygous mutation in the SOCS1 gene took place using genome sequencing. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 29 November 2022
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 7(127),p. 102-110
Significance of molecular and genetic research in hypochromic microcytic anemia refractory to ferrotherapy in the diagnosis of erythropoietic protoporphyria
Erythropoietic protoporphyria (EPP) is a rare hereditary disease that occurs worldwide, but there are regional differences in its epidemiology. The disease is caused by a partial deficiency of ferrochelatase, which is the last enzyme in the pathway of heme biosynthesis. In typical EPP, photosensitivity appears after first exposure to the sun in early childhood. Microcytic anemia is observed in 20-60% of registered EPP patients, which is mistakenly initially diagnosed as iron-deficiency anemia and prescribed iron-containing drugs. Purpose - is to present a clinical case of iron refractory hypochromic microcytic anemia in a four-month-old boy to improve the diagnosis of EPP. Clinical case. In the publication, we report on a 4-month-old boy in whom the disease debuted with hypochromic microcytic anemia refractory to the administration of iron preparations, target-like erythrocytes, normal indicators of iron metabolism, a slight enlargement of the spleen were found in the peripheral blood smear. The emphasis in the publication is on differential diagnosis, preventive measures and modern pathogenetic treatment with the latest approaches, which are aimed at solving the main defects at the molecular or cellular level, with the prospect of significantly improving the results of this orphan disease. Verification of the disease took place with the help of genome sequencing, a heterozygous pathogenic mutation FECH c.315-48T>C, characteristic of EPP which the child received from the father, was found. The experience of iron-refractory hypochromic microcytic anemia in a four-month-old boy gave grounds to expand the range of examinations, including hemoglobin electrophoresis and the use of molecular genetic studies, for differential diagnostic purposes. The report of this clinical case will be of informational value for family doctors, pediatricians, hematologists and a wide range of specialists. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 29 November 2022
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 7(127),p. 102-110
Significance of molecular and genetic research in hypochromic microcytic anemia refractory to ferrotherapy in the diagnosis of erythropoietic protoporphyria
Erythropoietic protoporphyria (EPP) is a rare hereditary disease that occurs worldwide, but there are regional differences in its epidemiology. The disease is caused by a partial deficiency of ferrochelatase, which is the last enzyme in the pathway of heme biosynthesis. In typical EPP, photosensitivity appears after first exposure to the sun in early childhood. Microcytic anemia is observed in 20-60% of registered EPP patients, which is mistakenly initially diagnosed as iron-deficiency anemia and prescribed iron-containing drugs. Purpose - is to present a clinical case of iron refractory hypochromic microcytic anemia in a four-month-old boy to improve the diagnosis of EPP. Clinical case. In the publication, we report on a 4-month-old boy in whom the disease debuted with hypochromic microcytic anemia refractory to the administration of iron preparations, target-like erythrocytes, normal indicators of iron metabolism, a slight enlargement of the spleen were found in the peripheral blood smear. The emphasis in the publication is on differential diagnosis, preventive measures and modern pathogenetic treatment with the latest approaches, which are aimed at solving the main defects at the molecular or cellular level, with the prospect of significantly improving the results of this orphan disease. Verification of the disease took place with the help of genome sequencing, a heterozygous pathogenic mutation FECH c.315-48T>C, characteristic of EPP which the child received from the father, was found. The experience of iron-refractory hypochromic microcytic anemia in a four-month-old boy gave grounds to expand the range of examinations, including hemoglobin electrophoresis and the use of molecular genetic studies, for differential diagnostic purposes. The report of this clinical case will be of informational value for family doctors, pediatricians, hematologists and a wide range of specialists. The research was carried out in accordance with the principles of the Helsinki Declaration. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
- 25 May 2020
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 3(107),p. 77-86
Parvovirus B19-viremia. Clinical and laboratory presentation
- 25 May 2020
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 3(107),p. 77-86
Parvovirus B19-viremia. Clinical and laboratory presentation
- 30 December 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 8(104),p. 71-82
Kikuchi–Fujimoto disease: features of diagnosis and clinical course
- 30 December 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 8(104),p. 71-82
Kikuchi–Fujimoto disease: features of diagnosis and clinical course
- 30 September 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 5(101),p. 9-30
Leukemoid reactions and chronic chronic myeloproliferative diseases in children: similarity and differences
- 30 September 2019
- Published by Group of Companies Med Expert, LLC in Modern pediatrics. Ukraine
- No. 5(101),p. 9-30
Leukemoid reactions and chronic chronic myeloproliferative diseases in children: similarity and differences
- 30 October 2017
- Published by Group of Companies Med Expert, LLC in SOVREMENNAYA PEDIATRIYA
- No. 6(86),p. 130-146
Down syndrome in the practice of haematologist
- 30 October 2017
- Published by Group of Companies Med Expert, LLC in SOVREMENNAYA PEDIATRIYA
- No. 6(86),p. 130-146
Down syndrome in the practice of haematologist